Triple-negative Breast Cancer Clinical Trial
Official title:
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
Status | Recruiting |
Enrollment | 80 |
Est. completion date | October 1, 2021 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age:18~75 years; 2. Triple-negative breast cancer (TNBC) confirmed by histology examination; 3. patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; 4. received endocrine therapy for metastatic disease before first-line chemotherapy were allowed; 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 6. A life expectancy of more than 12 weeks; 7. Baseline blood routine examination in accordance with the following criteria : ANC=1.5×109/L,PLT=90×109/L,Hb=90g/L; 8. Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases. the creatinine clearance rate calculated greater than 60 mL/min; 9. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose; 10. Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements. Exclusion Criteria: 1. Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy; 2. controlled high blood pressure, systolic blood pressure =150mmHg or diastolic blood pressure =100mmHg; 3. urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g; 4. abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN); 5. Pregnant or lactating woman; 6. Symptomatic brain parenchymal and/or pia mater metastases without treatment and control; 7. Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer; 8. Mental illness or other condition that affects patient compliance; 9. serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently; 10. Can not take or absorb oral drugs; 11. Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial; 12. The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative); 13. Known or suspected to be allergic to any research drug or excipient; 14. Any other researcher believes that it is not appropriate to participate in this test. |
Country | Name | City | State |
---|---|---|---|
China | Cancer hospital, ChineseAMS | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression-free survival | Time from randomization to disease progression or death for any cause | up to 6 months | |
Secondary | overall survival | Time from randomization to death for any cause | up to 6 months | |
Secondary | tine to progress | Time from randomization to disease progression | up to 6 months | |
Secondary | Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03639948 -
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT02427581 -
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 1 | |
Completed |
NCT04584112 -
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04914390 -
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
|
Phase 2 | |
Completed |
NCT03154749 -
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04582955 -
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
|
N/A | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03805399 -
FUSCC Refractory TNBC Umbrella (FUTURE)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04129996 -
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
|
Phase 2 | |
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05336721 -
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
|
Phase 2 | |
Terminated |
NCT03674827 -
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
|
Phase 1 | |
Completed |
NCT04177108 -
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
|
Phase 3 |